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Case report
CD34+-enriched donor lymphocyte infusions in a case of pure red cell
aplasia and late graft failure after major ABO-incompatible bone
marrow transplantation
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Division of Hematology, Federico II University Medical School, Naples, Italy
Summary:
A variety of immunohematological complications may
occur after ABO-incompatible BMT. We report a CML
patient (blood group O) who received a BMT from an
HLA-identical sibling (blood group AB). The transplant
was followed by normal myeloid and megakaryocytic
engraftment, but erythroblastopenia persisted for more
than 200 days after BMT. By bone marrow culture
studies, a complement-dependent serum inhibitor of
hemopoiesis was detected, suggesting immunological
inhibition of erythropoiesis. The patient was resistant to
a number of treatments such as intravenous gamma-
globulins, prednisolone and high-dose erythropoietin.
Full engraftment with normal blood counts and marrow
cellularity was achieved after two dose-escalating
CD34+-enriched donor lymphocyte infusions (DLI). This
experience suggests that CD34+-enriched DLI may be
an effective treatment for patients with delayed
engraftment or late graft failure due to major ABO-
incompatibility.
Keywords: PRCA; graft failure; DLI; CD34+ cells
Allogeneic bone marrow transplant with major ABO
incompatibility may be associated with delayed erythroid
engraftment that may either regress spontaneously or
become chronic. Acquired pure red cell aplasia (PRCA) has
been reported after major ABO-incompatible transplant
from peripheral blood1 or marrow,2 unmanipulated or T
cell-depleted progenitor cells. It is characterized by severe
anemia, reticulocytopenia and absence of erythroblasts in
otherwise normally engrafted bone marrow. Although
human parvovirus B19 may be a causative agent of PRCA
following BMT,3 more frequently autoimmune or alloim-
mune mechanisms have a role in its pathogenesis.4 A well-
recognized mechanism of PRCA complicating major ABO-
incompatible BMT involves antibodies towards red cell
precursors;2 a T cell-mediated suppression of erythropoiesis
has also been described.2 Management of PRCA after
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ABO-incompatible BMT is a difficult task; various
immunosuppressive regimens, erythropoietin and plas-
mapheresis have been used with variable results.2 Immune-
mediated mechanisms may also play a key role in the devel-
opment of late graft failure.5 Graft rescue by infusing
peripheral blood stem cells (PBSC) may be an effective
therapy for patients with early or late graft failure,6
whereas donor lymphocyte infusions (DLI) have been
primarily used for treating or preventing cytogenetic or
early hematological CML relapse.7
We report a case of PRCA followed by a progressive
graft failure complicating an ABO-incompatible allogeneic
BMT for CML in chronic phase, that was successfully
treated with CD34+-enriched DLI.
Case report
A 20-year-old woman underwent BMT from her HLA-
identical brother 6 months after the diagnosis of CML in
chronic phase. We used the conditioning regimen BU/CY2;
GVHD prophylaxis was carried out with CYA (2 mg/kg)
and short-course methotrexate. As the donor’s blood group
was AB (Rh: CcDee; Kell positive) and the recipient’s was
O (Rh: CCDee; Kell negative), erythrocyte-depleted
marrow containing 3.8 · 106/kg CD34+ cells and
2.54 · 104/kg CFU-GM was transplanted. Engraftment of
neutrophils and platelets was observed on days +23 and
+25, respectively. On day +30 laboratory findings were as
follows: Hb 9.6 g/dl; leukocytes 2.4 · 109/l with 66%
neutrophils, 30% lymphocytes, 4% monocytes; platelets
39 · 109/l; reticulocytes 0.1%; blood group O+. A bone
marrow aspirate revealed normal myeloid and megakary-
ocyte differentiation with severe erythroid hypoplasia (2%),
consistent with PRCA; a BM karyotype showed 81% 46
XY, 15% 46XX and 4% 46XX t(9;22) metaphases (Figure
1). Peripheral lymphocyte phenotyping showed normal
CD4/CD8 ratio. In vitro colony assay performed in methyl-
cellulose showed a marked decrease of erythroid burst-for-
ming units (BFU-E) with normal growth of myeloid pro-
genitors (Table 1). In a set of coculture experiments carried
out after a 2 h incubation of normal marrow cells with the
patient’s lymphocytes or serum, the growth of normal BFU-
E was clearly inhibited by the patient’s fresh serum and
not by heat inactivated serum (Table 1). There were no
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Figure 1 Hemoglobin, marrow erythropoiesis, blood group and karyotype modifications in the post-transplant period.
Table 1 Effects of patient’s lymphocytes and serum on colony formation from normal bone marrow cells before and after CD34+-enriched DLI
Before DLI After DLI
BFU-E CFU-GM BFU-E CFU-GM
Patient 6 6 5* 25 6 5** 34 6 4*** 28 6 1
Control + patient’s lymphocytes 34 6 6 44 6 6 35 6 6 39 6 6
Control + patient’s fresh serum 6 6 4 20 6 11 40 6 7**** 35 6 4
Control + patient’s heat inactivated serum 24 6 3 36 6 6 32 6 8 37 6 6
Control 30 6 4 40 6 5 36 6 4 47 6 5
Control + normal lymphocytes 32 6 6 45 6 1 41 6 6 49 6 4
Control + normal fresh AB serum 42 6 10 45 6 2 38 6 8 45 6 6
Control + normal heat inactivated AB serum 39 6 4 49 6 4 37 6 5 40 6 6
The values represent mean 6 s.d. of colony number/2 · 105 monocyte-depleted bone marrow cells plated in methylcellulose in the presence of rEPO 3
U/ml, rGM-CSF 50 ng/ml, rIL3 50 ng/ml, rSCF 50 ng/ml. Coculture experiments were carried out after 2 h incubation of marrow cells from a group
AB normal donor with patient’s lymphocytes (105/plate) or serum (100 ml/plate). Each experiment was performed in duplicate. Serum was heat inactivated
at 56 ° C for 1 h. The mean colony number from bone marrow of 25 normal controls was 35.4 6 16 erythroid and 30.7 6 10 myeloid colonies. Statistical
analysis (t-test): *P , 0.05 for comparison with control BFU-E; ***P , 0.05 for comparison with patient’s BFU-E before treatment; **P , 0.05 for
comparison with control CFU-GM; ****P , 0.05 for comparison with control BFU-E with patient’s fresh serum before treatment.
signs of hemorrhage, hemolysis or acute GVHD. During
the following 5 months, the patient was supported with
about five group O red cell concentrates per month, and
showed progressive reduction of allogeneic hemopoiesis
(Figure 1). In this period no circulating group AB red cells
were detectable, the Coomb’s test was persistently negative,
marrow examinations confirmed PRCA and no GVHD fea-
tures were observed. Likewise, serial analyses of the
patient’s serum and marrow cells for B19 parvovirus DNA
by nested-polymerase chain reaction showed no sign of
infection; even cytomegalovirus infection was excluded by
weekly checking CMV antigenemia. The patient was unre-
sponsive to several therapeutic attempts: a 5-day course of
intravenous immunoglobulins (0.4 g/kg/day); danazol (600
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mg/day for 2 months); bolus methylprednisolone (5
mg/kg/day for 5 days) followed by 1 month administration
of oral prednisone (1.5 mg/kg/day); 8 week administration
of subcutaneous erythropoietin (150 U/kg/day 3 days a
week) and a 5-day course of high-dose subcutaneous
erythropoietin (30 MU/day). Six months after BMT, the
karyotype showed a further decrease of allogeneic hemopo-
iesis (Figure 1) and CYA was discontinued. Anti-A and
anti-B isohemagglutinin titers, that were 1:1024 and 1:256,
respectively before transplant, still were 1:256 and 1:8 on
day +180. On day +195, G-CSF-mobilized (243 mg/day for
5 days) donor mononuclear cells containing 0.4 3 108/kg
CD3+ cells, 0.9 3 106/kg CD34+ cells and 1.8 3 104/kg
CFU-GM were infused without GVHD prophylaxis. Toler-
ance was excellent. Four weeks later, the patient received
an additional CD34+ enriched DLI containing 1 3 108/kg
CD3+ cells, 1.53 3 106/kg CD34+ cells and 3.8 3 104/kg
CFU-GM. Within 2 months of this treatment, Hb level, reti-
culocyte count and marrow erythropoiesis markedly
improved (12.2 g/dl, 2.1 3 1012/l and 50%, respectively),
with normalization of BFU-E growth at marrow culture; at
this time, there was no evidence of growth inhibition of
normal erythroid precursors by the patient’s serum (Table
1). A conversion of blood group from O to AB and a pro-
gressive increase of allogeneic hemopoiesis up to 100% of
mitoses were documented within 4 months (Figure 1),
together with signs of skin and mucosal chronic GVHD.
Twelve months after DLI the patient is in complete hemato-
logical remission with negative RT-PCR for bcr-abl; a lim-
ited cutaneous chronic GVHD is successfully controlled by
low-dose azathioprine. Anti-A and anti-B titers are now 1:4
and 1:2, respectively.
Discussion
Pure red cell aplasia following ABO-incompatible BMT is
attributed to an immune-mediated pathogenesis, by which
antibodies and/or cytotoxic lymphocytes may inhibit
erythroid progenitor cell proliferation.2 In our patient, in
vitro studies revealed that the patient’s fresh serum
inhibited normal marrow erythroid colony formation, sug-
gesting a complement-dependent inhibition of erythroid
progenitor cells. In addition, cytogenetic data documented
a progressive graft failure. G-CSF-mobilized allogeneic
PBSC have been found to be an effective and safe treatment
for patients with primary or late graft failure after BMT
for hematological diseases.6 Donor lymphocyte infusions
provide effective treatment for patients with CML (and for
a minority of patients with acute myeloid leukemia and
myelodysplastic syndrome) in early relapse after BMT;
however, DLI may be associated with severe or even lethal
myelosuppression or GVHD.7 It has been suggested that
DLI may eliminate or inactivate host-specific lymphocytes,
thus enhancing the engraftment through residual host T cell
killing or through a ‘veto’ activity;8,9 the same mechanisms
may mediate induction and maintenance of donor-specific
graft by CD34+ cells.10 Experimental studies in animal
models have also shown that G-CSF may modulate donor
T cell function by polarizing them towards type-2 cytokine
production, thus reducing the severity of acute GVHD.11
Based on the above considerations, we reasoned that in our
patient an appropriate treatment could be a combination of
DLI (immunomodulation and veto activity) with boosts of
donor CD34+ cells (to potentiate allogeneic hemopoiesis).
Such a combined treatment can be obtained by using
CD34+-enriched DLI. This is a feasible therapy for patients
with incomplete hematological reconstitution, who are
unresponsive to other treatments and thus at risk of graft
rejection. Further studies are needed to verify whether G-
CSF mobilization may reduce DLI-related complications
even in other settings.
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